(sterile cefoperazone, USP)
Formerly known as sterile cefoperazone sodium, USP
CEFOBID® (cefoperazone), formerly known as cefoperazone sodium, is a sterile, semisynthetic, broad-spectrum, parenteral cephalosporin antibiotic for intravenous or intramuscular administration. It is the sodium salt of 7-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(p -hydroxyphenyl)acetamido-3-[[(1-methyl- H -tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2. 0]oct-2-ene-2-carboxylate.
CEFOBID is indicated for the treatment of the following infections when caused by susceptible organisms:
Respiratory Tract Infections caused by S. pneumoniae, H. influenzae, S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes (Group A beta-hemolytic streptococci), P. aeruginosa, Klebsiella pneumoniae, E. coli, Proteus mirabilis, and Enterobacter species.
Peritonitis and Other Intra-abdominal Infections caused by E. coli, P. aeruginosa and anaerobic gram-negative bacilli (including Bacteroides fragilis).
Bacterial Septicemia caused by S. pneumoniae, S. agalactiae, S. aureus, Pseudomonas aeruginosa, E. coli, Klebsiella spp., Klebsiella pneumoniae, Proteus species (indole-positive and indole-negative), Clostridium spp. and anaerobic gram-positive cocci.
Infections of the Skin and Skin Structures caused by S. aureus (penicillinase and non-penicillinase producing strains), S. pyogenes, and P. aeruginosa.
Pelvic Inflammatory Disease, Endometritis, and Other Infections of the Female Genital Tract caused by N. gonorrhoeae, S. epidermidis, S. agalactiae, E. coli, Clostridium spp., Bacteroides species (including Bacteroides fragilis), and anaerobic gram-positive cocci.
Cefobid, like other cephalosporins, has no activity against Chlamydia trachomatis. Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added.
Urinary Tract Infections caused by Escherichia coli and Pseudomonas aeruginosa.
Enterococcal Infections: Although cefoperazone has been shown to be clinically effective in the treatment of infections caused by enterococci in cases of peritonitis and other intra-abdominal infections, infections of the skin and skin structures, pelvic inflammatory disease, endometritis and other infections of the female genital tract, and urinary tract infections, the majority of clinical isolates of enterococci tested are not susceptible to cefoperazone but fall just at or in the intermediate zone of susceptibility, and are moderately resistant to cefoperazone. However, in vitro susceptibility testing may not correlate directly with in vivo results. Despite this, cefoperazone therapy has resulted in clinical cures of enterococcal infections, chiefly in polymicrobial infections. Cefoperazone should be used in enterococcal infections with care and at doses that achieve satisfactory serum levels of cefoperazone.
Before instituting treatment with CEFOBID, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Treatment may be started before results of susceptibility testing are available.
Published Studies Related to Cefobid (Cefoperazone)
Comparison of sulbactam-cefoperazone with carbapenems as empirical monotherapy for febrile neutropenic children with lymphoma and solid tumors. [2011.05]
Febrile neutropenia (FEN) is a leading complication of intensive chemotherapy. With this prospective randomized study, the authors aimed to compare the effectiveness of sulbactam-cefoperazone (SC) versus carbapenems, as empirical monotherapy in febrile neutropenic children with lymphoma and solid tumors.
Bioequivalence study of the two 1.5 g cefoperazone and sulbactam IM injections in Thai healthy male volunteers. [2008.11]
CONCLUSION: The 1.5 g cefoperazone and sulbactam injection of Cefper and Sulperazone used in the present study are bioequivalent.
Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India. [2008.06]
BACKGROUND: Combinations of a third-generation cephalosporin and metronidazole, with or without an aminoglycoside, often are used for the treatment of intra-abdominal infections in surgical settings. Simpler regimens that preserve an adequate spectrum of coverage, but allow easier administration and have fewer side effects, may be a more desirable option... CONCLUSION: Empirical cefoperazone-sulbactam monotherapy could be a useful adjunct to surgical intervention for intra-abdominal infections.
Randomized comparison of piperacillin-tazobactam plus amikacin versus
cefoperazone-sulbactam plus amikacin for management of febrile neutropenia in
children with lymphoma and solid tumors. 
The objective of this study was to compare the effectiveness of
piperacillin-tazobactam (PIP/TAZO) plus amikacin (AMK) (PIP/TAZO+AMK) versus
cefoperazone-sulbactam (CS) plus AMK (CS+AMK) for the treatment of febrile
neutropenia (FN) in children with cancer... Both combinations were effective and safe as empirical
therapy for febrile neutropenic patients.
Augmentation in zone of inhibition of cefoperazone/cefoperazone+ sulbactum compares well with the clinical laboratory standard institute standard extended spectrum Beta-lactamase detection method as well as the polymerase chain reaction method. [2011.07.01]
Background: With increased prevalence of extended spectrum beta-lactamase (ESBL) in hospital practice globally, reporting of extended spectrum beta-lactamase along with drug susceptibility test is expected from clinical microbiology laboratory. The aim was to evaluate cefoperazone and cefoperazone+sulbactum disc for phenotypic detection of extended spectrum beta-lactamase among E.
Clinical Trials Related to Cefobid (Cefoperazone)
Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis [Recruiting]
Strategy of antibiotic therapy in SAP,De-escalate (cefoperazone+metronidazole) or Escalate
(meropenem) therapy,which one is better.
A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections [Completed]
Intra-abdominal infections are often polymicrobial, and include aerobic as well as anaerobic
bacteria. Antibiotics used in intra-abdominal infections should aim to cover organisms such
as Enterobacteriaceae and Bacteroides fragilis, which are the commonest organisms known to
cause such infections. Combinations of a third-generation cephalosporin, an aminoglycoside
and metronidazole are often used to treat such infections in surgical settings. An
alternative to such combinations is the use of a beta lactam - beta lactamase inhibitor
combination. Magnex (cefoperazone- sulbactam) is one such combination, which has been shown
to be as effective as a standard multidrug regimen such as gentamicin and clindamycin in the
management of intra-abdominal infections. The combination of ceftazidime, amikacin and
metronidazole has been chosen as a comparator regimen because of its broad coverage of
Gram-negative and anaerobic organisms found in such conditions.
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections. [Withdrawn]
The primary objective is to collect data on treatment outcomes (clinical and microbiological
cure), safety and tolerability of treatment with cefoperazone/sulbactam in patients with
serious intra-abdominal and hepatobiliary infections in Slovakia.
The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline [Not yet recruiting]
The mortality of pneumonia with extensively drug resistant Acinetobacter baumannii (XDRAB)
is still high, even if these patients received certain strong anti-infection treatment such
us the combination of cefoperazone-sulbactam (C/S) and minocycline. Health airway lining
fluid is mildly alkaline but airway acidification usually appears for the infection of
XDRAB. The hypothesis is offered that the biologic activity of XDRAB might be inhibited if
the circumstance including pH is changed. In the vitro study we observed that the inhibit
effect of antibiotics on XDRAB growth was improved significantly by alkaline solution within
the scope of physiology. So the aim of this clinical study is to explore the effects of
nebulization of alkaline Solution on C/S plus minocycline on the pneumonia with XDRAB.
An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia [Enrolling by invitation]
This is a phase III, multi-center, open-label, comparative and randomized study in
evaluating the efficacy and safety of cefoperazone/sulbactam versus cefepime for the
treatment of hospital-acquired pneumonia and healthcare-associated pneumonia. The
investigator will determine the total duration of study therapy, as clinically indicated.
The minimum duration of study therapy will be 7 days and the maximum allowable duration of
study therapy will be 21 days.